SI2680834T1 - A semi-aqueous aqueous pharmaceutical composition containing tapentadol - Google Patents

A semi-aqueous aqueous pharmaceutical composition containing tapentadol Download PDF

Info

Publication number
SI2680834T1
SI2680834T1 SI201231143T SI201231143T SI2680834T1 SI 2680834 T1 SI2680834 T1 SI 2680834T1 SI 201231143 T SI201231143 T SI 201231143T SI 201231143 T SI201231143 T SI 201231143T SI 2680834 T1 SI2680834 T1 SI 2680834T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
composition according
tapentadol
aqueous
composition containing
Prior art date
Application number
SI201231143T
Other languages
English (en)
Slovenian (sl)
Inventor
Ulrich Reinhold
Marc Schiller
Eva Wulsten
Sabine Karine Katrien Inghelbrecht
Roger Carolus Augusta Embrechts
Ulrich Feil
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI2680834T1 publication Critical patent/SI2680834T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI201231143T 2011-03-04 2012-03-02 A semi-aqueous aqueous pharmaceutical composition containing tapentadol SI2680834T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
EP12710026.1A EP2680834B1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
SI2680834T1 true SI2680834T1 (en) 2018-01-31

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231143T SI2680834T1 (en) 2011-03-04 2012-03-02 A semi-aqueous aqueous pharmaceutical composition containing tapentadol

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP2680834B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR102039320B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA025194B1 (enExample)
ES (2) ES2654407T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX344473B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT3766489T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
NO2680834T3 (enExample) 2011-05-03 2018-03-17
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
AU2016239772B2 (en) * 2015-03-27 2021-05-13 Grünenthal GmbH Stable formulation for parenteral administration of Tapentadol
JP7160799B2 (ja) * 2016-09-23 2022-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与用安定製剤
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound
BR112021018439A2 (pt) 2019-03-18 2021-11-23 Sunstar Americas Inc Composição para higiene bucal

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
AU2003225837B2 (en) 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
CN100344328C (zh) 2002-09-13 2007-10-24 锡德克斯公司 以衍生环糊精稳定化的含有水性填充组合物的胶囊
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
PL1786403T3 (pl) 2004-07-01 2013-10-31 Gruenenthal Gmbh Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol
US20110098284A1 (en) 2005-04-28 2011-04-28 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
EP2010145A2 (en) * 2006-04-25 2009-01-07 Croda, Inc. Modification of percutaneous absorption of topically active materials
ATE494889T1 (de) 2006-04-28 2011-01-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
PT2012763E (pt) 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
SI2046726T1 (sl) 2006-07-24 2010-05-31 Janssen Pharmaceutica Nv Priprava R R metoksifenil N N trimetilpentanamina
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP3170494A3 (en) 2007-11-23 2017-09-06 Grünenthal GmbH Tapentadol compositions
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
JP6216489B2 (ja) * 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
BR112012024835A2 (pt) * 2010-03-30 2016-06-07 Phosphagenics Ltd adesivo de distribuição transdérmica
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
NO2680834T3 (enExample) * 2011-05-03 2018-03-17

Also Published As

Publication number Publication date
EP2680834A1 (en) 2014-01-08
JP6259042B2 (ja) 2018-01-10
US20160346229A1 (en) 2016-12-01
CA2828637A1 (en) 2012-09-13
JP6670283B2 (ja) 2020-03-18
KR102039320B1 (ko) 2019-11-01
IL227826A0 (en) 2013-09-30
IL258357A (en) 2018-05-31
EA201300988A1 (ru) 2014-06-30
JP6027549B2 (ja) 2016-11-16
KR20180116463A (ko) 2018-10-24
KR20140013020A (ko) 2014-02-04
EA033171B1 (ru) 2019-09-30
NO2680834T3 (enExample) 2018-03-17
JP2017039756A (ja) 2017-02-23
LT2680834T (lt) 2018-01-10
EA201600442A1 (ru) 2017-02-28
MX344473B (es) 2016-12-16
HUE037491T2 (hu) 2018-09-28
US9446008B2 (en) 2016-09-20
MX2013010100A (es) 2013-10-01
CN103501774A (zh) 2014-01-08
AU2012224954A1 (en) 2013-09-19
PL2680834T3 (pl) 2018-03-30
PT3766489T (pt) 2022-04-07
EP2680834B1 (en) 2017-10-18
US20180133174A1 (en) 2018-05-17
EP3766489A1 (en) 2021-01-20
WO2012119729A1 (en) 2012-09-13
EA025194B1 (ru) 2016-11-30
JP2014506900A (ja) 2014-03-20
DK2680834T3 (en) 2017-12-04
AU2012224954B2 (en) 2016-10-20
BR112013022556A2 (pt) 2016-12-06
MX374468B (es) 2025-03-06
JP2018065839A (ja) 2018-04-26
ES2910085T3 (es) 2022-05-11
EP3290029A1 (en) 2018-03-07
AU2017200040B2 (en) 2018-09-06
CY1119725T1 (el) 2018-06-27
RS56692B1 (sr) 2018-03-30
EP3766489B1 (en) 2022-03-16
IL227826B (en) 2018-04-30
HRP20171836T1 (hr) 2017-12-29
ES2654407T3 (es) 2018-02-13
CA2828637C (en) 2019-06-11
AU2012224954C1 (en) 2017-04-06
EP3290029B1 (en) 2020-09-02
US20120225950A1 (en) 2012-09-06
PT2680834T (pt) 2018-01-25
KR101911362B1 (ko) 2018-10-25
ZA201306480B (en) 2014-05-28
AU2017200040A1 (en) 2017-02-02
BR112013022556A8 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
SI2680834T1 (en) A semi-aqueous aqueous pharmaceutical composition containing tapentadol
BR112014029766A2 (pt) composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas
HRP20210085T1 (hr) Pripravci i postupci za liječenje disfunkcije meibomske žlijezde
BR112017024934A2 (pt) composições farmacêuticas tópicas
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
HRP20230726T1 (hr) Topikalna formulacija za poticanje zarastanja rana
JP2014517028A5 (enExample)
NZ591205A (en) Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
JP7664689B2 (ja) 外用組成物
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
HRP20191059T1 (hr) Skup aktivnih sastojaka za topikalnu primjenu u restrukturiranju izmijenjene kožne barijere poslije kožnih bolesti
BR112014026596A2 (pt) composição pesticida sinérgica
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
SI3057664T1 (en) Use of a composition for the pigmentation of hair and hairs
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
BRPI0417116A (pt) usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação
HRP20200504T1 (hr) Lokalni preparati farmaceutskih i medicinskih proizvoda koji sadrže kombinacije sukralfata, hijaluronske kiseline, arginina i prirodnog hidratantnog sredstva
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
SI2874614T1 (en) Water-soluble film which has a healing effect
WO2015100348A8 (en) Keloid reduction using topical allantoin
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
WO2012008457A1 (ja) 外用組成物